Abid Husain
Cardiovascular Disease · Englewood, CONPI 1669585618
Payments from drug & device makers
Across 296 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Amgen$1K
- Kowa Pharmaceuticals America, Inc.$556
- Novo Nordisk$511
- AstraZeneca$347
- Esperion Therapeutics, Inc.$294
- plus $1K from 23 others
What the payments were for
- Food & beverage$5,14898%
- Education$822%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 70 | $1,218 |
| Amgen | 87 | $1,139 |
| Kowa Pharmaceuticals America, Inc. | 15 | $556 |
| Novo Nordisk | 23 | $511 |
| AstraZeneca | 24 | $347 |
| Esperion Therapeutics, Inc. | 15 | $294 |
| Boehringer Ingelheim | 11 | $224 |
| Bayer | 6 | $104 |
| Amarin Pharma, Inc. | 5 | $93 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $82 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $70 |
| Pfizer | 3 | $62 |
| Lundbeck LLC | 3 | $57 |
| Heartflow, Inc. | 3 | $54 |
| Johnson & Johnson | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Cvrx, Inc. | 1 | $44 |
| Idorsia Pharmaceuticals US Inc | 3 | $41 |
| Lilly USA, LLC | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Abbott | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Abiomed | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Biotronik Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Cleerly, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,229 in reported general payments places this provider in the 65th percentile of 276 cardiovascular disease providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 58 | $40,872 |
| MounjaroTirzepatide | 22 | $30,876 |
| JardianceEmpagliflozin | 24 | $29,696 |
| OzempicSemaglutide | 17 | $29,668 |
| Praluent PenAlirocumab | 24 | $16,841 |
| NexletolBempedoic Acid | 13 | $13,292 |
| Telmisartan | 49 | $1,610 |
| Ezetimibe | 19 | $924 |
| Rosuvastatin Calcium | 48 | $497 |
| Amlodipine Besylate | 12 | $104 |
| Chlorthalidone | 13 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $30 | $30,87622 claims |
| Boehringer IngelheimJardiance | $224 | $29,69624 claims |
| Novo NordiskOzempic | $511 | $29,66817 claims |
| Esperion Therapeutics, Inc.Nexletol | $294 | $13,29213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Englewood
- Juan Marmol-VelezEnglewood$21K
- Gary LuckasenFort Collins$11M
- Payal KohliAurora$1.7M
- Marc BonacaAurora$1.2M
- William SauerAurora$978K
- John AltmanLakewood$797K
- Nampalli VijayDenver$711K
- Brack HattlerAurora$699K
- Lin-Wang DongGreeley$640K
- Jake ChaninDenver$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.